A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
Crossref DOI link: https://doi.org/10.21037/tlcr-20-649
Published Online: 2021-01
Published Print: 2021-01
Update policy: https://doi.org/10.21037/ame_crossmark_policy
Okajima, Masaaki
Miura, Satoru
Watanabe, Satoshi
Tanaka, Hiroshi
Ito, Kazuhiko
Ishida, Takashi
Makino, Masato
Iwashima, Akira
Matsumoto, Naoya
Sato, Kazuhiro
Ichikawa, Kosuke
Abe, Tetsuya
Yoshizawa, Hirohisa
Kikuchi, Toshiaki